Skip to main content

Osteochondral Defect

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Arthrex
ArthrexCA - Santa Barbara
1 program
BioCartilage® Micronized Cartilage MatrixN/A1 trial
Active Trials
NCT03696394Unknown15Est. Nov 2023
Organogenesis
OrganogenesisCANTON, MA
1 program
ReNuN/A1 trial
Active Trials
NCT03036878Terminated1Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ArthrexBioCartilage® Micronized Cartilage Matrix
OrganogenesisReNu

Clinical Trials (2)

Total enrollment: 16 patients across 2 trials

NCT03696394ArthrexBioCartilage® Micronized Cartilage Matrix

A Study to Evaluate the Efficacy of BioCartilage® Micronized Cartilage Matrix in Microfracture Treatment of Osteochondral Defects

Start: Jan 2019Est. completion: Nov 202315 patients
N/AUnknown

ReNu™ Marrow Stimulation Augmentation

Start: Feb 2017Est. completion: Dec 20191 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.